Nothing Special   »   [go: up one dir, main page]

JO3404B1 - تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين - Google Patents

تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين

Info

Publication number
JO3404B1
JO3404B1 JOP/2001/0065A JOP20010065A JO3404B1 JO 3404 B1 JO3404 B1 JO 3404B1 JO P20010065 A JOP20010065 A JO P20010065A JO 3404 B1 JO3404 B1 JO 3404B1
Authority
JO
Jordan
Prior art keywords
span
strong
pharmaceutical formulation
formulation containing
liquid pharmaceutical
Prior art date
Application number
JOP/2001/0065A
Other languages
English (en)
Inventor
Papadimitriou Apollon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of JO3404B1 publication Critical patent/JO3404B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<strong><span dir="RTL">يتعلق الختراع الحاي بتركيب دوائي سائل يشتمل على بروتين إريثروبويتين (</span></strong>erythropoietin<strong><span dir="RTL">)، أنيون غير عضوي متعدد الشحنة في مادة ضبط أس هيدروجيني مقبولة دوائيا مناسبة لحفظ الأس الهيدروجيني للمحلول في مستوى من حوالي 5,5 الى حوالي 7، و إختياريا واحدة أو أكثر من مواد مسوغة مقبولة دوائيا. هذا التركيب نافع خصيصا للوقاية من و علاج أمراض متعلقة بتكوين الكريات الحمراء.</span></strong>
JOP/2001/0065A 2000-05-15 2001-05-09 تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين JO3404B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110355 2000-05-15

Publications (1)

Publication Number Publication Date
JO3404B1 true JO3404B1 (ar) 2019-10-20

Family

ID=8168722

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2001/0065A JO3404B1 (ar) 2000-05-15 2001-05-09 تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين

Country Status (35)

Country Link
US (2) US7169754B2 (ar)
EP (2) EP1525889A1 (ar)
JP (1) JP3967594B2 (ar)
KR (3) KR20070032815A (ar)
CN (1) CN1309416C (ar)
AR (2) AR035034A1 (ar)
AT (1) ATE291436T2 (ar)
AU (1) AU784091B2 (ar)
BR (1) BRPI0110914B8 (ar)
CA (1) CA2408685C (ar)
CZ (1) CZ304855B6 (ar)
DE (1) DE60109625T3 (ar)
DK (1) DK1311285T4 (ar)
EC (2) ECSP024352A (ar)
ES (1) ES2237574T5 (ar)
HR (1) HRP20020880B1 (ar)
HU (1) HU230874B1 (ar)
IL (2) IL152659A0 (ar)
JO (1) JO3404B1 (ar)
MA (1) MA26901A1 (ar)
ME (1) ME00673B (ar)
MX (1) MXPA02011303A (ar)
MY (1) MY128654A (ar)
NO (1) NO330934B1 (ar)
NZ (1) NZ522030A (ar)
PE (1) PE20020050A1 (ar)
PL (1) PL219131B1 (ar)
PT (1) PT1311285E (ar)
RS (1) RS51292B (ar)
RU (1) RU2281116C2 (ar)
SI (1) SI1311285T1 (ar)
TW (2) TWI288643B (ar)
UY (1) UY26704A1 (ar)
WO (1) WO2001087329A1 (ar)
ZA (1) ZA200208500B (ar)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
KR20070032815A (ko) 2000-05-15 2007-03-22 에프. 호프만-라 로슈 아게 신규한 약학 조성물
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
DE60144439D1 (de) * 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
JP2003152145A (ja) * 2001-08-31 2003-05-23 Sumitomo Electric Ind Ltd 半導体放熱用基板とその製造方法及びパッケージ
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1545586A4 (en) * 2002-09-09 2007-09-26 Warren Pharmaceuticals Inc LONG-ACTING ERYTHROPOIETINES THAT MAINTAIN THE PROTECTIVE ACTIVITY OF THE TISSUE OF ENDOGENEURY ERYTHROPOIETIN
ZA200502320B (en) * 2002-09-20 2006-10-25 Pharmacia Corp Process for decreasing aggregate levels of pegylated protein
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7803777B2 (en) * 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US7691603B2 (en) * 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) * 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
JP2007523630A (ja) * 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
CA2525568C (en) * 2003-05-12 2017-07-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
BRPI0411166A (pt) 2003-05-12 2006-07-18 Affymax Inc composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
ES2385888T3 (es) 2003-06-10 2012-08-02 Lg Life Sciences Ltd. Solución acuosa estable de eritropoyetina humana que no contiene albúmina sérica
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
AU2004293103C1 (en) * 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
PL1696947T3 (pl) 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
CA2552892C (en) * 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2005074650A2 (en) * 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
DE102004011663B4 (de) * 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
JPWO2005089743A1 (ja) * 2004-03-19 2008-01-31 味の素株式会社 腎性貧血治療剤
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
JP2007530578A (ja) * 2004-03-26 2007-11-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エリスロポエチンのための組合せ投薬養生方法
AR049580A1 (es) * 2004-07-07 2006-08-16 Lundbeck & Co As H Epo carbamilada y metodo para su produccion
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006031811A2 (en) * 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
ES2566670T3 (es) * 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008526864A (ja) * 2005-01-06 2008-07-24 ネオス テクノロジーズ インコーポレイテッド 糖断片を用いる糖結合
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20090311247A1 (en) * 2005-01-25 2009-12-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
WO2006105426A2 (en) * 2005-03-30 2006-10-05 Neose Technologies, Inc. Manufacturing process for the production of peptides grown in insect cell lines
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070037886A1 (en) * 2005-04-26 2007-02-15 Ajinomoto Co., Inc. Bone marrow erythroid progenitor cell(s) differentiation inducer
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2007037795A2 (en) * 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
AU2006280932A1 (en) * 2005-08-19 2007-02-22 Novo Nordisk A/S Glycopegylated factor VII and factor Vila
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
JP5553506B2 (ja) * 2006-03-22 2014-07-16 中外製薬株式会社 エリスロポエチン溶液製剤
JP2009544327A (ja) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
JP5723528B2 (ja) * 2006-08-04 2015-05-27 プロロング ファーマシューティカルズ エルエルシー 修飾されたエリスロポエチン
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
AU2007319657B9 (en) * 2006-10-04 2019-10-31 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
KR20100052501A (ko) 2007-08-27 2010-05-19 바이오제너릭스 에이지 Ｇ―ｃｓｆ 콘주게이트의 액상 포뮬레이션
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SMT202000436T1 (it) 2008-08-14 2020-09-10 Acceleron Pharma Inc Trappole di gdf
JP5632376B2 (ja) * 2008-09-23 2014-11-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エリスロポエチンの精製
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
CN102460147A (zh) 2009-06-24 2012-05-16 弗·哈夫曼-拉罗切有限公司 可重复使用的色谱设备的鉴定
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
NZ712943A (en) * 2009-08-13 2017-08-25 Acceleron Pharma Inc Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
EP2480569B1 (en) * 2009-09-23 2016-04-13 ratiopharm GmbH Process for the purification of recombinant human erythropoietin (epo)
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP5621052B2 (ja) 2010-12-21 2014-11-05 エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ クロマトグラフィー装置の特徴決定
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
BR112015009948B1 (pt) 2012-11-02 2022-12-06 Celgene Corporation Uso de um inibidor de actrii
CU20140003A7 (es) 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
WO2015150930A1 (en) * 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of conjugated erythropoietin
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2019129878A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
CN111558046A (zh) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用
TWI740635B (zh) * 2020-09-09 2021-09-21 財團法人工業技術研究院 聚偏氟乙烯薄膜組成物及聚偏氟乙烯隔離膜

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115833A (en) * 1871-06-13 Improvement in grain-driers
US147431A (en) * 1874-02-10 Improvement in game boards
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
DE4135542A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Lagerfaehige proteinloesungen
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CA2262994A1 (en) † 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5919656A (en) * 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
EP0885613A1 (de) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
PT1123313E (pt) 1998-10-23 2007-04-30 Amgen Inc Métodos e composições para a prevenção e tratamento da anemia
UY25790A1 (es) 1998-11-06 2000-08-21 Bio Sidus S A Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2000061169A1 (en) † 1999-04-09 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (ar) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي مشتقات الأريرثروبويتين
EA006220B1 (ru) 1999-07-22 2005-10-27 Авентис Фармасьютиклс, Инк. Многодозовые эритропоэтиновые составы
US7253142B1 (en) † 1999-09-08 2007-08-07 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
KR20070032815A (ko) * 2000-05-15 2007-03-22 에프. 호프만-라 로슈 아게 신규한 약학 조성물
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
US20040147431A1 (en) 2004-07-29
IL152659A (en) 2010-12-30
CA2408685A1 (en) 2001-11-22
EP1311285B2 (en) 2017-04-12
DK1311285T4 (en) 2017-07-24
AR092919A2 (es) 2015-05-06
US7202208B2 (en) 2007-04-10
SI1311285T1 (ar) 2005-08-31
CZ304855B6 (cs) 2014-12-10
NO330934B1 (no) 2011-08-22
PL361341A1 (pl) 2004-10-04
KR20030001509A (ko) 2003-01-06
HUP0302114A2 (hu) 2003-10-28
MEP90708A (hr) 2011-12-20
PE20020050A1 (es) 2002-02-01
KR20050121762A (ko) 2005-12-27
DE60109625T3 (de) 2017-08-03
CN1429116A (zh) 2003-07-09
WO2001087329A1 (en) 2001-11-22
ZA200208500B (en) 2004-01-28
CN1309416C (zh) 2007-04-11
JP3967594B2 (ja) 2007-08-29
BRPI0110914B8 (pt) 2021-05-25
ECSP024352A (es) 2003-03-31
TWI288644B (en) 2007-10-21
ES2237574T3 (es) 2005-08-01
ES2237574T5 (es) 2017-08-09
EP1311285B1 (en) 2005-03-23
UY26704A1 (es) 2001-12-28
KR20070032815A (ko) 2007-03-22
US7169754B2 (en) 2007-01-30
BR0110914A (pt) 2003-02-11
ATE291436T2 (de) 2005-04-15
RS51292B (sr) 2010-12-31
ME00673B (me) 2011-12-20
DK1311285T3 (da) 2005-06-27
EP1525889A1 (en) 2005-04-27
MA26901A1 (fr) 2004-12-20
RU2281116C2 (ru) 2006-08-10
WO2001087329A8 (en) 2002-03-07
EP1311285A2 (en) 2003-05-21
NO20025450L (no) 2002-11-14
CA2408685C (en) 2011-02-01
HUP0302114A3 (en) 2012-12-28
AR035034A1 (es) 2004-04-14
AU6593401A (en) 2001-11-26
AU784091B2 (en) 2006-02-02
DE60109625T2 (de) 2006-03-30
HU230874B1 (hu) 2018-11-29
NO20025450D0 (no) 2002-11-14
HK1056683A1 (en) 2004-02-27
KR100758044B1 (ko) 2007-09-11
MY128654A (en) 2007-02-28
US20020037841A1 (en) 2002-03-28
PT1311285E (pt) 2005-06-30
JP2003533487A (ja) 2003-11-11
HRP20020880A2 (en) 2004-12-31
DE60109625D1 (de) 2005-04-28
BRPI0110914B1 (pt) 2016-03-01
PL219131B1 (pl) 2015-03-31
HRP20020880B1 (en) 2006-04-30
ECSP10004352A (es) 2011-01-31
YU83502A (sh) 2005-11-28
IL152659A0 (en) 2003-06-24
CZ20024005A3 (cs) 2004-01-14
TWI288643B (en) 2007-10-21
MXPA02011303A (es) 2003-04-25
NZ522030A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
TR200003158T2 (tr) Jelleşebilen farmasötik bileşimler
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
NO964864D0 (no) Orale, flytende alendronatpreparater
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
BG105173A (en) Novel salt form of pantoprazole
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
HUP0000125A2 (hu) Folyékony alendronátkészítmények, valamint eljárás azok előállítására
SE0001916D0 (sv) Novel formulation
EE200200695A (et) (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
GEP20043377B (en) Pharmaceutical Complex
MY122477A (en) Sertraline oral concentrate
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
WO2001051489A3 (en) Methods for lowering uric acid levels
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására